Novartis has received a positive opinion from CHMP and EMA on the supply of the medical product Leqvio. This is the only siRNA-based medication in Europe with a new mechanism of action. The European Commission will soon consider the conclusion of CHMP to sell the drug in 27 EU countries. The drug is also under consideration by the FDA.